Human herpesvirus‐8‐related Kaposi's sarcoma after liver transplantation successfully treated with cidofovir and liposomal daunorubicin

: The iatrogenic form of Kaposi's sarcoma (KS) is typically observed among transplant recipients, and the most appropriate therapeutic approach (usually including reduction of immunosuppression, specific chemotherapy, and/or administration of antiviral agents against human herpes virus‐8) is st...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Transplant infectious disease Ročník 7; číslo 1; s. 34 - 37
Hlavní autoři: Verucchi, G., Calza, L., Trevisani, F., Zambruni, A., Tadolini, M., Giuliani, R., Manfredi, R., Andreone, P., Chiodo, F., Bernardi, M.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Oxford, UK Munksgaard International Publishers 01.03.2005
Témata:
Antibiotics, Antineoplastic - therapeutic use
Antiviral Agents - therapeutic use
cidofovir
Cytosine - analogs & derivatives
Cytosine - therapeutic use
daunorubicin
Daunorubicin - therapeutic use
Drug Therapy, Combination
Herpesvirus 8, Human - isolation & purification
human herpes virus‐8
Humans
Immunocompromised Host
Kaposi's sarcoma
liver transplantation
Liver Transplantation - adverse effects
Male
Middle Aged
Organophosphonates - therapeutic use
Sarcoma, Kaposi - drug therapy
Sarcoma, Kaposi - virology
Viral Load
Viremia
ISSN:1398-2273, 1399-3062
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:: The iatrogenic form of Kaposi's sarcoma (KS) is typically observed among transplant recipients, and the most appropriate therapeutic approach (usually including reduction of immunosuppression, specific chemotherapy, and/or administration of antiviral agents against human herpes virus‐8) is still controversial. Available experiences on the effect of the anti‐herpes viruses drug cidofovir provide conflicting results. Herein, we report the clinical, histological, and virological features of a liver transplant recipient successfully treated with a combined therapy of cidofovir and liposomal daunorubicin, associated with a reduction of the immunosuppressive regimen, for an advanced cutaneous and visceral KS.
Bibliografie:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1398-2273
1399-3062
DOI:10.1111/j.1399-3062.2005.00081.x